Who are AZD6244 Dosing Period 4's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEFACTINIB, Encorafenib and Binimetinib, Tunlametinib plus Vemurafenib, Trametinib tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd6244-dosing-period-4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AZD6244 Dosing Period 4 — Competitive Intelligence Brief

AZD6244 Dosing Period 4 (AZD6244 Dosing Period 4) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MEK inhibitor. Area: Oncology.

phase 1 MEK inhibitor MEK1/2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD6244 Dosing Period 4 (AZD6244 Dosing Period 4) — AstraZeneca. AZD6244 is a selective inhibitor of MEK1/2, which are key components of the RAS-RAF-MEK-ERK signaling pathway.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD6244 Dosing Period 4 TARGET	AZD6244 Dosing Period 4	AstraZeneca	phase 1	MEK inhibitor	MEK1/2
DEFACTINIB	DEFACTINIB		marketed		MEK1/2, ERK1/2, FAK, Pyk2
Encorafenib and Binimetinib	Encorafenib and Binimetinib	Pierre Fabre Medicament	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E/K and MEK1/2
Tunlametinib plus Vemurafenib	Tunlametinib plus Vemurafenib	Shanghai Kechow Pharma, Inc.	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E and MEK1/2
Trametinib tablet	Trametinib tablet	West China Hospital	phase 3	MEK inhibitor	MEK1 and MEK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MEK inhibitor class)

AstraZeneca · 4 drugs in this class
Array Biopharma, now a wholly owned subsidiary of Pfizer · 3 drugs in this class
Atriva Therapeutics GmbH · 1 drug in this class
IDEAYA Biosciences · 1 drug in this class
Pierre Fabre Medicament · 1 drug in this class
West China Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD6244 Dosing Period 4 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd6244-dosing-period-4. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab